SCHEMBL30349338

SCHEMBL30349338

Cc1ccc(S(=O)(=O)n2cc(I)c3cnc(C4CCC4)nc32)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 1/20 0.42
▸ BRD4 O60885 2/20 0.40
▸ L3MBTL1 Q9Y468 3/20 0.38
▸ MCOLN3 Q8TDD5 1/20 0.38
▸ POLB P06746 3/20 0.37
▸ HTT P42858 3/20 0.37
▸ LMNA P02545 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ ALDH3A1 P30838 1/20 0.37
▸ NOD1 Q9Y239 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ UBE2N P61088 1/20 0.36
▸ HTR6 P50406 3/20 0.35
▸ PKM P14618 2/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ KLK7 P49862 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25523066 1.00 ACHE (0.42) ACHEBRD4L3MBTL1MCOLN3POLB
SCHEMBL12120920 0.79 ABL1 (0.44) BRD4L3MBTL1POLBHTTALDH3A1
SCHEMBL25158303 0.77 TGFBR1 (0.37) ACHEL3MBTL1POLBHTTLMNA
SCHEMBL30349147 0.77 TGFBR1 (0.37) ACHEL3MBTL1POLBHTTLMNA
SCHEMBL13834845 0.77 BRD4 (0.45) BRD4L3MBTL1POLBHTTLMNA
SCHEMBL29283857 0.75 L3MBTL1 (0.44) BRD4L3MBTL1POLBHTTLMNA
SCHEMBL31006563 0.75 L3MBTL1 (0.44) BRD4L3MBTL1POLBHTTLMNA
SCHEMBL19250316 0.73 BRD4 (0.54) BRD4L3MBTL1POLBHTTLMNA
SCHEMBL30461664 0.73 ALDH1A1 (0.43) BRD4L3MBTL1POLBHTTLMNA
SCHEMBL25419377 0.73 ALDH1A1 (0.43) BRD4L3MBTL1POLBHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP disclosed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 ACHE 3151/4885BRD4 1417/4885L3MBTL1 2548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback